This review summarizes the role of metalloproteinases and their inhibitors in extracellular matrix remodeling across high-incidence pathologies including obesity, liver fibrosis, and cardiovascular disease.
Extracellular matrix (ECM) remodeling is required for many physiological and pathological processes. Metalloproteinases (MMPs) are endopeptidases which are able to degrade different components of the ECM and nucleus matrix and to cleave numerous non-ECM proteins. Among pathological processes, MMPs are involved in adipose tissue expansion, liver fibrosis, and atherosclerotic plaque development and vulnerability. The expression and the activity of these enzymes are regulated by different hormones and growth factors, such as insulin, leptin, and adiponectin. The controversial results reported up to this moment regarding MMPs behavior in ECM biology could be consequence of the different expression patterns among species and the stage of the studied pathology. The aim of the present review was to update the knowledge of the role of MMPs and its inhibitors in ECM remodeling in high incidence pathologies such as obesity, liver fibrosis, and cardiovascular disease.
Berg et al. (2019) conducted a review in Obesity, liver fibrosis, and cardiovascular disease. Metalloproteinases (MMPs) and inhibitors was evaluated. This review summarizes the role of metalloproteinases and their inhibitors in extracellular matrix remodeling across high-incidence pathologies including obesity, liver fibrosis, and cardiovascular disease.